Effect of supplementation in treatment of polycystic ovary syndrome

Effects of chromium supplementation on hormonal status in women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201506105623N44

Enrollment

Registered

2015-06-27

Start date

2015-06-22

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: Chromium tablet, 200 µg, daily, for 8 weeks orally. Intervention 2: Control group: Placebo tablet, daily, for 8 weeks orally.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Women aged 18-40 years old diagnosed with PCOS

Exclusion criteria

Exclusion criteria: Individuals with elevated levels of prolactin Thyroid disorder Endocrine diseases including diabetes or impaired glucose tolerance Gastrointestinal problems

Design outcomes

Primary

Measure	Time frame
Free testosterone. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.	—

Secondary

Measure	Time frame
Prolactin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;FSH. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;LH. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Total antioxidant. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;17-OH progesterone. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;DHEA. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.	—

Measure

Time frame

Prolactin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;FSH. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;LH. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Total antioxidant. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;17-OH progesterone. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;DHEA. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 14, 2026